Charles River Laboratories International (NYSE:CRL) Sets New 52-Week High – Here’s Why

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $230.52 and last traded at $231.7270, with a volume of 110118 shares changing hands. The stock had previously closed at $226.79.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CRL. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and lifted their target price for the stock from $167.00 to $219.00 in a report on Friday, May 29th. Barclays increased their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, Robert W. Baird set a $213.00 price objective on Charles River Laboratories International in a research report on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $215.88.

Charles River Laboratories International Stock Performance

The firm has a market cap of $11.35 billion, a price-to-earnings ratio of -62.66, a price-to-earnings-growth ratio of 2.58 and a beta of 1.46. The stock has a 50-day moving average of $178.79 and a 200-day moving average of $183.83. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the prior year, the firm posted $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. National Bank of Canada FI lifted its position in shares of Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares during the period. Gotham Asset Management LLC raised its stake in Charles River Laboratories International by 17.3% in the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock valued at $49,403,000 after purchasing an additional 46,594 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in Charles River Laboratories International during the fourth quarter worth about $1,223,000. Nordea Investment Management AB lifted its position in Charles River Laboratories International by 43.6% during the fourth quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after purchasing an additional 16,616 shares during the period. Finally, Confluence Investment Management LLC grew its stake in Charles River Laboratories International by 10.1% during the fourth quarter. Confluence Investment Management LLC now owns 105,626 shares of the medical research company’s stock worth $21,070,000 after buying an additional 9,663 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.